Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) by Mogensen, Ulrik M. et al.
European Journal of Heart Failure (2018) RESEARCH ARTICLE
doi:10.1002/ejhf.1139
Effect of sacubitril/valsartan on recurrent
events in the Prospective comparison of ARNI
with ACEI to Determine Impact on Global
Mortality and morbidity in Heart Failure trial
(PARADIGM-HF)
Ulrik M. Mogensen1,2, Jianjian Gong3, Pardeep S. Jhund1, Li Shen1, Lars Køber2,
Akshay S. Desai4, Martin P. Lefkowitz3, Milton Packer5, Jean L. Rouleau6,
Scott D. Solomon4, Brian L. Claggett4, Karl Swedberg7, Michael R. Zile8,
Guenther Mueller-Velten9, and John J.V. McMurray1,*
1BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 2Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; 3Novartis Pharmaceutical
Corporation, East Hanover, NJ, USA; 4Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 5Baylor Heart and Vascular Institute, Baylor University
Medical Center, Dallas, TX, USA; 6Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada; 7Department of Molecular and Clinical Medicine, University of
Gothenburg, Gothenburg, Sweden, and National Heart and Lung Institute, Imperial College, London, UK; 8Medical University of South Carolina and Ralph H. Johnson Veterans
Administration Medical Center, Charleston, SC, USA; and 9Novartis Pharma AG, Basel, Switzerland
Received 22 September 2017; revised 18 December 2017; accepted 21 December 2017
Aims Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses
consider only the first event. We compared the effect of sacubitril/valsartan vs. enalapril on recurrent events,
incorporating all HF hospitalizations and cardiovascular (CV) deaths in PARADIGM-HF, using a variety of statistical
approaches advocated for this type of analysis.
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Methods
and results
In PARADIGM-HF, a total of 8399 patients were randomized and followed for a median of 27months. We applied
various recurrent event analyses, including a negative binomial model, the Wei, Lin and Weissfeld (WLW), and Lin,
Wei, Ying and Yang (LWYY) methods, and a joint frailty model, all adjusted for treatment and region. Among a
total of 3181 primary endpoint events (including 1251 CV deaths) during the trial, only 2031 (63.8%) were first
events (836 CV deaths). Among a total of 1195 patients with at least one HF hospitalization, 410 (34%) had at
least one further HF hospitalization. Sacubitril/valsartan compared with enalapril reduced the risk of recurrent HF
hospitalization using the negative binomial model [rate ratio (RR) 0.77, 95% confidence interval (CI) 0.67–0.89], the
WLW method [hazard ratio (HR) 0.79, 95% CI 0.71–0.89], the LWYY method (RR 0.78, 95% CI 0.68–0.90), and
the joint frailty model (HR 0.75, 95% CI 0.66–0.86) (all P < 0.001). The effect of sacubitril/valsartan vs. enalapril on
recurrent HF hospitalizations/CV death was similar.
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Conclusions In PARADIGM-HF, approximately one third of patients with a primary endpoint (time-to-first) experienced a further
event. Compared with enalapril, sacubitril/valsartan reduced both first and recurrent events. The treatment effect
size was similar, regardless of the statistical approach applied.
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Introduction
Recently, it has been suggested that analysis of recurrent non-fatal,
along with fatal, events might be a better means of evaluating the
true burden of heart failure (HF) as a disease and the effect of
treatment, than the conventional time-to-first event analysis.1–7
Although most life-saving therapies also reduce the risk of admis-
sion to hospital with worsening HF, hospitalization remains a com-
mon problem, readmission is frequent and the total number of
admissions during a patient’s life accounts for the greatest propor-
tion of the overall cost of the illness. Assessing the effect of treat-
ment on the time-to-first admission does not, therefore, reflect
its impact on the full burden of disease, especially as it is possible
that the efficacy of treatment may decline over time or patients
with repeat admissions might represent a subset of those resistant
to therapy. Consequently, we have examined the effect of sacu-
bitril/valsartan (previously described as LCZ696), an angiotensin
receptor neprilysin inhibitor (ARNI), compared with enalapril, on
repeat as well as first hospitalizations and the totality of events
[i.e. HF admissions and cardiovascular (CV) deaths], a pre-specified
exploratory analysis, in the Prospective comparison of ARNI with
ACEI to Determine Impact on Global Mortality and morbidity in
Heart Failure trial (PARADIGM-HF).8,9 In addition to this clinical
question there is also a question about the choice of statistical
method to evaluate the effect of treatment on recurrent events.2–7
Analysis of recurrent hospitalizations in an unbiased way is difficult
because of the competing risk of death and potentially different
follow-up times in the different treatment groups if one therapy
is more effective than the other in reducing mortality. At present,
there is no single method that has gained universal acceptance and
for that reason we have compared a number of different analytical
approaches that have been applied to this problem. We used these
various methods to compare the effect of sacubitril/valsartan to
enalapril on recurrent events in PARADIGM-HF.
Methods
Study design and patients
The PARADIGM-HF trial (ClinicalTrials.gov ID number:
NCT01035255) has been described in detail previously and the
results published.8–10 Patients had New York Heart Association
(NYHA) class II–IV symptoms, an ejection fraction ≤40% (changed to
≤35% by amendment), and a plasma B-type natriuretic peptide (BNP)
≥150 pg/mL [or N-terminal pro-BNP (NT-proBNP) ≥600 pg/mL].
Patients who had been hospitalized for HF within 12months were eli-
gible with a lower natriuretic peptide concentration (BNP ≥100 pg/mL
or NT-proBNP ≥400 pg/mL). Patients were required to be taking
an angiotensin-converting enzyme (ACE) inhibitor or angiotensin
receptor blocker (ARB) in a dose equivalent to enalapril 10mg
daily for at least 4weeks before screening, along with a stable dose
of a beta-blocker (unless contraindicated or not tolerated) and a
mineralocorticoid receptor antagonist (if indicated). The exclusion
criteria included history of intolerance to ACE inhibitors or ARBs,
symptomatic hypotension (or a systolic blood pressure<100mmHg
at screening/<95mmHg at randomization), an estimated glomerular
filtration rate (eGFR) <30mL/min/1.73m2, a serum potassium con-
centration> 5.2mmol/L at screening (>5.4mmol/L at randomization), ..
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.. and a history of angioedema. After a run-in period [during which
patients had to tolerate enalapril 10mg twice daily for 2weeks
(single-blind) and then sacubitril/valsartan (single-blind) for an addi-
tional 4 to 6weeks, initially at 49/51mg twice daily and then 97/103mg
twice daily], patients were randomized to either enalapril 10mg twice
daily or sacubitril/valsartan 97/103mg twice daily.
PARADIGM-HF was conducted in accordance with the Declaration
of Helsinki. The Ethics Committee of each of the 1043 participating
institutions in 47 countries approved the protocol, and all patients gave
written informed consent.
Outcomes
The primary outcome of PARADIGM-HF was a composite of death
from CV causes or a first hospitalization for HF. HF hospitalizations
were adjudicated by a clinical events committee according to standard-
ized definitions. All deaths were also classified by the committee.
Statistical analyses
Recurrent events are commonly analysed using count data methods
(e.g. negative binomial regressions), and using time to event data meth-
ods [e.g. Wei, Lin and Weissfeld (WLW),11 and Lin, Wei, Ying and Yang
(LWYY)12 models], all of which are extensions of Cox proportional
hazards regression. More recently the joint frailty model has been used
to examine recurrent events with a competing terminal event.4,5 The
methods used in the current analyses were pre-specified in the trial
statistical analysis plan.13 We calculated the HF hospitalization rate by
treatment group by dividing the total number of HF hospitalizations
by the total number of follow-up years in each group. The cumulative
rates of HF hospitalizations over time by treatment group were plotted
as cumulative incidence curves using the non-parametric Ghosh and
Lin method, accounting for the competing risk of death.14 The effect
of sacubitril/valsartan compared to enalapril on all HF hospitalizations
and on the composite of all HF hospitalizations and CV death was
analysed using the LWYY, WLW, negative binomial and joint frailty
methods. For the WLW method, we estimated time to the i-th HF
hospitalization and time to the i-th HF hospitalization including CV
death as an event for i=1 to 6.
The effect of sacubitril/valsartan compared to enalapril was modelled
adjusting for the randomization stratification variable of region. All
analyses were repeated with adjustment for differences in baseline
characteristics including age, sex, heart rate, eGFR, left ventricular
ejection fraction, body mass index, NYHA class, duration of HF,
history of HF hospitalization, hypertension, diabetes, atrial fibrillation,
myocardial infarction, stroke, and log NT-proBNP.
A two-sided P-value of <0.05 was considered significant. The analy-
ses were undertaken using R version 3.2.3, SAS version 9.4 (SAS Insti-
tute Inc., Cary, NC, USA), and Stata version 14 (Stata Corp., College
Station, TX, USA).
Results
In the enalapril group (n = 4212), 658 patients (15.6%) had at
least one hospitalization for HF; the respective number in the
sacubitril/valsartan group (n = 4187) was 537 (12.8%) (Table 1). In
the enalapril group, 418 patients had one admission for HF, 143 had
two admissions, and 97 had≥3 admissions during the trial (Table 1).
The corresponding numbers in the sacubitril/valsartan group were
367, 110, and 60. The total number of admissions for HF was 1079
in the enalapril group and 851 in the sacubitril/valsartan group.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Number of patients with endpoint event and number of endpoint events per patient
HF hospitalization Composite of CV death and
HF hospitalization
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sacubitril/valsartan Enalapril Sacubitril/valsartan Enalapril
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n 4187 4212 4187 4212
Events per patient
0 3650 (87.2%) 3554 (84.4%) 3273 (78.2%) 3095 (73.5%)
1 367 (8.8%) 418 (9.9%) 629 (15.0%) 751 (17.8%)
2 110 (2.6%) 143 (3.4%) 186 (4.4%) 204 (4.8%)
3 33 (0.8%) 53 (1.3%) 59 (1.4%) 96 (2.3%)
4 9 (0.2%) 22 (0.5%) 17 (0.4%) 34 (0.8%)
5 5 (0.1%) 16 (0.4%) 7 (0.2%) 17 (0.4%)
6 3 (0.1%) 2 (0%) 5 (0.1%) 11 (0.3%)
7 6 (0.1%) 1 (0%) 4 (0.1%) 1 (0%)
8 1 (0%) 0 (0%) 4 (0.1%) 0 (0%)
9 2 (0%) 2 (0%) 0 (0%) 0 (0%)
10 0 (0%) 0 (0%) 2 (0%) 2 (0%)
11 0 (0%) 1 (0%) 0 (0%) 1 (0%)
18 1 (0%) 0 (0%) 1 (0%) 0 (0%)
At least one event 537 (12.8%) 658 (15.6%) 914 (21.8%) 1117 (26.5%)
At least two events 170 (4.1%) 240 (5.7%) 285 (6.8%) 366 (8.7%)
Total events 851 1079 1409 1772
Total follow-up years 9308 9235 9308 9235
Total CV deaths 558 (13.3%) 693 (16.5%)
Total all-cause deaths 711 (17.0%) 835 (19.8%)
CV, cardiovascular; HF, heart failure.
Baseline characteristics of hospitalized
patients
The characteristics of patients who were not hospitalized during
follow-up, those who were admitted once and those admitted two
or more times are shown in Table 2. Patients who were admitted
were older, more likely to be male and from North America, to
have more severe HF as assessed by length of diagnosis, health
status (NYHA class and KCCQ score), renal function, natriuretic
peptide levels, co-morbidity and diuretic and digoxin use. Patients
admitted for worsening HF during follow-up were more likely to
have been admitted previously (before enrolment in the trial). Of
those not admitted during follow-up, 61% had a history of HF hos-
pitalization; of those admitted once, 72% had a prior admission and
of those admitted twice or more, 81% had a previous admission.
Compared with patients admitted once, those admitted more
than once were more often male (87% vs. 78%, P < 0.001), more
often had diabetes (51% vs. 43%, P = 0.006) and renal disease (30%
vs. 23%, P = 0.007), while differences in the prevalence of chronic
obstructive pulmonary disease was not significant (21% vs. 17%,
P < 0.001). All these findings were similar when comparing base-
line characteristics according to number of HF hospitalizations/CV
death during follow-up, except that chronic obstructive pulmonary
disease was significantly more frequent among patients admitted
more than once compared with those admitted once (20% vs.
14%, P = 0.001) (supplementary material online, Table S1). ..
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.. Effect of sacubitril/valsartan compared
with enalapril
Table 1 shows the proportion of patients with one or one or
more hospitalizations for HF. Figures 1–3 show the effect of
sacubitril/valsartan, compared with enalapril, on recurrent events.
There was a reduction in the proportion of patients with
one or one or more HF hospitalizations. These reductions were
not offset by an increase in risk of other CV admissions or
non-CV hospitalizations, despite the longer survival time in the
sacubitril/valsartan group (data not shown).
Both the cumulative incidence method (Nelson-Aalen esti-
mator, where death is considered as independent censoring)
and the Ghosh and Lin method (where death is handled as
informative censoring, i.e. incorporated as a competing risk
recognizing zero hospitalizations after death) demonstrated
that the number of HF hospitalizations was lower in the
sacubitril/valsartan compared to the enalapril group (Figure
1). This effect was evident early in the trial and was consis-
tent after the initial 6months as more events accumulated
(Figure 2).
Several recurrent event analyses were used to examine the effect
of sacubitril/valsartan on recurrent HF hospitalizations (Figure 3).
Compared to the estimate using a traditional time-to-first event
analysis [hazard ratio (HR) 0.79, 95% confidence interval (CI)
0.71–0.89, P < 0.001], sacubitril/valsartan reduced the number of
HF hospitalizations to a very similar degree regardless of the
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics by number of hospitalizations during follow-up
0 hospitalization (n = 7204) 1 hospitalization (n = 785) ≥2 hospitalizations (n = 410) P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at screening (years) 63.7±11.4 64.4±11.5 65.0±11.5 0.022
Female sex 1609 (22.3%) 171 (21.8%) 52 (12.7%) <0.001
Region <0.001
North America 460 (6.4%) 85 (10.8%) 57 (13.9%)
Latin America 1285 (17.8%) 107 (13.6%) 41 (10.0%)
Western Europe 1751 (24.3%) 204 (26.0%) 96 (23.4%)
Central Europe 2413 (33.5%) 272 (34.6%) 141 (34.4%)
Asia/Pacific and other 1295 (18.0%) 117 (14.9%) 75 (18.3%)
Race <0.001
White 4725 (65.6%) 541 (68.9%) 278 (67.8%)
Black 343 (4.8%) 54 (6.9%) 31 (7.6%)
Asia 1311 (18.2%) 121 (15.4%) 77 (18.8%)
Other 825 (11.5%) 69 (8.8%) 24 (5.9%)
Systolic blood pressure (mmHg) 121.5±15.2 120.4±15.9 121.1±16.2 0.131
Heart rate (beats per minute) 72.1±11.9 73.8±12.9 74.3±12.3 <0.001
eGFR (mL/min/1.73m2) 68.3± 20.1 64.2±18.9 63.2± 22.1 <0.001
Serum creatinine (μmol/L) 98.2± 25.8 104.4± 28.4 108.9± 28.9 <0.001
Ischaemic HF aetiology 4311 (59.8%) 466 (59.4%) 259 (63.2%) 0.383
Ejection fraction (%) 29.6± 6.2 28.6± 6.5 28.6± 6.7 <0.001
Body mass index (kg/m2) 28.1± 5.5 28.7± 5.7 28.8± 6.2 <0.001
Current smoking 1030 (14.3%) 118 (15.0%) 60 (14.6%) 0.847
NYHA class <0.001
I 355 (4.9%) 24 (3.1%) 10 (2.4%)
II 5121 (71.2%) 524 (66.8%) 274 (67.0%)
III 1671 (23.2%) 226 (28.8%) 121 (29.6%)
IV 45 (0.6%) 11 (1.4%) 4 (1.0%)
Duration of HF <0.001
≤1 year 2298 (31.9%) 159 (20.3%) 66 (16.1%)
1–5 years 2740 (38.0%) 325 (41.4%) 167 (40.7%)
>5 years 2166 (30.1%) 301 (38.3%) 177 (43.2%)
A history of
Hypertension 5052 (70.1%) 577 (73.5%) 311 (75.9%) 0.009
Diabetes 2364 (32.8%) 334 (42.5%) 209 (51.0%) <0.001
Myocardial infarction 3069 (42.6%) 370 (47.1%) 195 (47.6%) 0.010
Valvular heart disease 463 (6.4%) 78 (9.9%) 63 (15.4%) <0.001
Atrial fibrillation 2561 (35.5%) 336 (42.8%) 194 (47.3%) <0.001
HF hospitalization 4378 (60.8%) 565 (72.0%) 331 (80.7%) <0.001
Stroke 597 (8.3%) 79 (10.1%) 49 (12.0%) 0.012
COPD 864 (12.0%) 132 (16.8%) 84 (20.5%) <0.001
Cancer 341 (4.7%) 46 (5.9%) 26 (6.3%) 0.150
Renal disease 1148 (15.9%) 181 (23.1%) 124 (30.2%) <0.001
Use of
Beta-blocker 6718 (93.3%) 722 (92.0%) 371 (90.5%) 0.051
MRA 3989 (55.4%) 451 (57.5%) 231 (56.3%) 0.513
Diuretic 5679 (78.8%) 691 (88.0%) 368 (89.8%) <0.001
Digoxin 2130 (29.6%) 259 (33.0%) 150 (36.6%) 0.002
Any ICD (including CRT-D) 985 (13.7%) 166 (21.1%) 92 (22.4%) <0.001
CRT 449 (6.2%) 77 (9.8%) 48 (11.7%) <0.001
BNP (pg/mL) 256 [251–262] 362 [339–387] 400 [363–439] <0.001
NT-proBNP (pg/mL) 1651 [1615–1687] 2383 [2220–2557] 2674 [2424–2948] <0.001
KCCQ clinical summary score 76.7±19.0 72.1± 20.9 69.4± 20.1 <0.001
BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy-defibrillation;
eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; KCCQ, Kansas City Cardiomyopathy Questionnaire; MRA,
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
*P-value is for comparison between 1 hospitalization and ≥2 hospitalizations.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Cumulative rate of heart failure hospitalizations (A) and the primary composite endpoint (B).
Figure 2 Ratio (sacubitril/valsartan vs. enalapril) for the conditional rate of cumulative heart failure hospitalizations (A) and the primary
composite endpoint (B).
methods used. The LWYY proportional rates model gave a rate
ratio (RR) of 0.78 (95% CI 0.68–0.90, P < 0.001). TheWLWmodel
gave an overall HR of 0.79 (95% CI 0.71–0.89, P < 0.001). The HRs
for the first and subsequent hospitalizations were similar (Table
3). The unadjusted RR from the negative binomial model for all
HF hospitalizations was very similar to the other models (0.77,
95% CI 0.67–0.89, P < 0.001). When CV death was added to the
negative binomial model as a composite endpoint, the reduction
in HF hospitalizations and CV death with sacubitril/valsartan was
essentially unchanged. The joint frailty model also gave a similar
estimate of the effect of sacubitril/valsartan on recurrent HF
hospitalizations when CV death was accounted for (RR 0.75, 95%
CI 0.66–0.86, P < 0.001). Adjusting the above models for the
differences in baseline characteristics according to number of HF
hospitalizations made little difference to the estimates (Figure 3).
Excluding patients with an extreme number of hospitalizations (11
or 18 HF hospitalizations) yielded similar results (data not shown). ..
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. Discussion
The analysis of PARADIGM-HF shows that even in individuals with
predominantly mild symptoms, 658 of 4212 patients (16%) in the
enalapril group were admitted at least once with worsening HF
in a relatively short period (median follow-up 27months), despite
excellent pharmacologic therapy. Of these 658 patients, 240 (36%)
were readmitted more than once and experienced a total of
661 admissions. Although important from a personal and societal
perspective, the repeat (i.e. second or subsequent) hospitalizations
(n = 421) experienced by these patients are not counted in a
conventional time-to-first event analysis, despite accounting for
39% of all admissions for HF in the enalapril group.
Therefore, there is increasing recognition that assessment of the
full burden of HF necessitates consideration of repeat events.2–7
Similarly, to be truly effective, the benefit of treatment must
be maintained after an initial hospitalization. In other fields (e.g.
cancer and infection), the effectiveness of treatment may be less
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
6 U.M. Mogensen et al.
Figure 3 Treatment effect of sacubitril/valsartan compared with enalapril according to different methods in unadjusted and adjusted
analyses. Adj, adjusted; CI, confidence interval; HF, heart failure; HR, hazard ratio; LWYY, Lin, Wei, Ying and Yang method; RR, rate ratio;
Unadj, unadjusted; WLW, Wei, Lin and Weissfeld method. HR and RR have a similar interpretation: HR represents the common ratio
(sacubitril/valsartan over enalapril) of the instantaneous risk at any time while RR represents the common ratio of the expected change in
the cumulative rate of events over time.
on recurrent events. Theoretically, pathophysiological processes
such as re-activation of the renin–angiotensin–aldosterone sys-
tem or treatment tachyphylaxis could reduce the effect of sacu-
bitril/valsartan or enalapril on second and subsequent events. The
difficulty, however, is choosing the statistical method to evaluate
the effect of treatment on repeat events. The analysis of recur-
rent hospitalizations is challenging because of the competing risk
of death and different follow-up times in the different treatment
groups. Hospitalization and death are clearly related in that death
leads to loss of sicker individuals more likely to be hospitalized (and,
conversely, hospitalization is associated with a higher subsequent .
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. risk of death). Longer survival and follow-up time means a longer
time at risk of admission and a difference in hospitalization rate
could reflect an effect of treatment on death alone. This is partic-
ular true for the non-parametric method of Ghosh and Lin, which
adjusts estimates of cumulative recurrent hospitalization rates over
time for differences in death rate and the follow-up time observed
in the study by explicitly accounting for the fact that patients who
have died will subsequently have zero hospitalizations.14
The negative binomial model, on the other hand, can be consid-
ered as a method that implicitly employs model-based estimation
of missing count data for patients with incomplete follow-up by
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Hazard ratios (sacubitril/valsartan vs.
enalapril) from the Wei, Lin and Weissfeld model for
the first and subsequent hospitalizations for heart
failure
Unadjusted
HR (95% CI)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hospitalization for HF
Time to 1st 0.80 (0.71–0.89) <0.001
Time to 2nd 0.69 (0.57–0.84) <0.001
Time to 3rd 0.61 (0.44–0.84) 0.002
Time to 4th 0.60 (0.37–0.98) 0.04
Time to 5th 0.81 (0.43–1.51) 0.50
Time to 6th 2.14 (0.81–5.65) 0.12
Average 0.79 (0.71–0.89) <0.001
Hospitalization for HF, including
CV death as an eventa
Time to 1st 0.80 (0.73–0.87) <0.001
Time to 2nd 0.79 (0.71–0.88) <0.001
Time to 3rd 0.78 (0.70–0.87) <0.001
Time to 4th 0.79 (0.71–0.88) <0.001
Time to 5th 0.80 (0.72–0.89) <0.001
Time to 6th 0.81 (0.72–0.90) <0.001
Average 0.80 (0.73–0.87) <0.001
CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio.
aIf a patient experienced CV death prior to event no. 6, then CV death was also
included for this patient’s subsequent event numbers up to event no. 6.
assuming that the counts for HF hospitalizations that would have
been collected if a patient had not died (or had not been lost to
follow-up or censored) were missing at random. It is assumed that
rates follow a Poisson distribution for each subject, and that rates
are constant and proportional, conditional on a subject-specific
frailty. The resulting effect estimate can be interpreted as a
marginal RR or ratio of expected number of endpoint events,
assuming a latent process continuing after death. An advantage
of the negative binomial regression is that it is easy to use, that
correlation of events in the same individual is naturally accounted
for through the inclusion of a random effect term, and that the
resulting effect size estimates are easy to interpret. However, it
has the disadvantage in that it assumes a constant event rate and
cannot examine potential time-varying effects.
The WLW model uses a total-time approach considering times
from randomization to the first, second and subsequent events.
HRs from a Cox proportional hazards model for each ordered
event (e.g. hospitalization) are combined to give an ‘average effect’,
although, in this case, the individual HRs do provide evidence of
a sustained effect of treatment beyond the first hospitalization.
For the analysis of the composite primary endpoint, the weight
of CV death in the combined statistic is greater than that of the
i-th HF hospitalization (i=1, ..., 6). In this example, if a patient
dies from a CV reason without a prior HF hospitalization, then CV
death will be counted six times before weighting in the combined
statistic (i.e. the estimated treatment effect size can be considered
as weighted towards CV death). While preserving randomization, ..
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.. the WLW approach has been criticized because it assumes that a
patient is at risk for a second event before having experienced a first
event.15
The LWYY model is based on a gap-time approach consider-
ing the time since a previous event (or the inter-event times), and
is essentially a modified Andersen and Gill model,16 with a robust
variance estimator (sandwich estimator) to account for the depen-
dency of within-subject events. In the LWYY model, the two rate
functions for having an event over any given time period in each
treatment group are assumed, conditional on being at risk and not
having died from CV reasons, to be proportional to each other.
Loss to follow-up and death due to non-CV reasons are considered
as independent censorings. This approach accounts for the fact that
counting process is not defined after death and has the disadvan-
tage of potentially diluting estimates of the treatment effect if the
drug reduces both HF hospitalization and death.
The joint frailty model estimates a RR for HF hospitalization,
whilst incorporating the competing risk of CV death, and a HR
for CV death that allows for HF hospitalizations. This approach
is appealing in that it allows a distinct treatment effect to be
estimated for each of the individual outcomes while taking account
of the association between the two through a common ‘frailty
term’. Here, ‘frailty’ refers to a subject-specific random term
that accounts for the fact that some patients are at higher risk
(larger frailty) than others (smaller frailty) of experiencing HF
hospitalization and CV death. Compared with the WLW and
Ghosh and Lin method, use of a joint frailty model has been
found to give more unbiased estimates of treatment effect in
the presence of dependent censoring (correlation between HF
hospitalization and CV death).17 However, this approach is limited
in two aspects. First, the resulting RR is not a marginal estimate but
is conditional on having the same frailty. Second, it assumes that the
individual-specific frailties affect each outcome in the same way and
that the model correctly captures this relationship.
While CV deaths were handled as competing risks (informative
censoring) in the joint frailty model, deaths due to non-CV reasons
were handled as non-informative censoring. Non-CV deaths were
also handled as non-informative censoring in the LWYY, the WLW,
and the negative binomial methods. In PARADIGM-HF, the majority
of deaths were due to CV causes (81%) and the rate of non-CV
causes was almost equal in the two treatment groups [enalapril,
n =142 (3.4%) vs. sacubitril/valsartan, n =153 (3.7%)]. Thus, there
was no indication that the competing risk of non-CV deaths biased
the estimated treatment effects.
All analytical methods used to evaluate the effect of study drug
on total events (first and subsequent) gave consistent estimates of
the treatment effect, similar to the time-to-first event although,
in some cases, with slightly wider 95% CIs. The joint frailty
model showed a greater reduction in the rate of recurrent HF
hospitalizations (i.e. larger treatment effect), presumably due to
accounting for the correlation with CV death, for which a hazard
reduction of 20% was observed in the sacubitril/valsartan group
in PARADIGM-HF. Relative to the LWYY approach, for which
a slight dilution of treatment effect was expected due to the
positive effect of sacubitril/valsartan on CV death, the negative
binomial model showed slightly more reduction in the rate of both
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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HF hospitalization and the composite endpoint of CV death and
recurrent HF hospitalization.
Analyses of recurrent events have an advantage over the
traditional time-to-first-event approach in capturing treatment
effects on the total disease burden, and it may increase statisti-
cal power. The European Medicines Agency guidance for trials
on therapies for chronic HF acknowledges recurrent HF hos-
pitalizations as a potentially acceptable primary endpoint, while
highlighting the importance of adjudication of events and a clear
methodological strategy.18 The United States Food and Drug
Administration has also accepted the use of recurrent events as
a primary outcome,19–21 but none of the regulatory bodies have
recommended a single or specific statistical approach.
We are not able to recommend any statistical method over
another based on the present study, but find it reassuring that
each method gave overall similar estimates of the treatment
effect. Until a consensus on the analysis of recurrent events has
been established, the method or methods used will depend on
trial-specific regulatory guidance. We are aware of at least one new
trial in HF which has analysis of recurrent events as its primary
endpoint.21
In summary, although each of the statistical methods described
has strengths and weaknesses, in PARADIGM-HF, where the inves-
tigational treatment reduced both CV death and HF hospitalization
individually, each analytical approach gave a similar estimate of the
effect of sacubitril/valsartan on total (i.e. first and recurrent) events.
Sacubitril/valsartan was superior to enalapril not just in reducing
first events but also total events, with a similar treatment effect
size on all events as seen on first events. Consequently, the abso-
lute treatment benefit was considerably larger when total events
were considered (54 vs. 29 fewer hospitalizations per 1000 patients
treated over a median of 27months).
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version of this article:
Table S1. Baseline characteristics by number of hospitaliza-
tions/cardiovascular death during follow-up.
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